Despite earlier concerns over its low efficacy rate, the Chinese-made Sinovac COVID-19 vaccine appears to be performing well in its largest test to date in Chile, according to the findings by the Financial Times’ Senior Data-Visualization Journalist John Burn-Murdoch.
Sinovac’s 50.4% efficacy rate that was derived from phase three clinical trials in Brazil, related to mild cases only. What Burn-Murdoch’s reporting shows is that the vaccine is successfully protecting people from becoming seriously ill and keeping them out of the intensive care unit.
- Get a daily email packed with the latest China-Africa news and analysis.
- Read exclusive insights on the key trends shaping China-Africa relations.
- Full access to the News Feed that provides daily updates on Chinese engagement in Africa and throughout the Global South.